Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics. The authors identify differences between responders and nonresponders and recommend controlled trials.
Goff
D C
DC
Erich Lindemann Mental Health Center, Massachusetts General Hospital, Boston.
Brotman
A W
AW
Waites
M
M
McCormick
S
S
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D005473:Fluoxetine